[ad_1] Alnylam tumbles, BridgeBio gains after heart drug data [ad_2] Source: Seekingalpha
Browsing: data
[ad_1] Alnylam falls after full data for heart drug that can rival Pfizer’s [ad_2] Source: Seekingalpha
[ad_1] Alnylam tumbles, BridgeBio gains after heart drug data [ad_2] Source: Seekingalpha
[ad_1] Alnylam falls after full data for heart drug that can rival Pfizer’s [ad_2] Source: Seekingalpha
[ad_1] Alnylam tumbles, BridgeBio gains after heart drug data [ad_2] Source: Seekingalpha
[ad_1] Gain slips after early-stage data for Parkinson’s therapy [ad_2] Source: Seekingalpha
[ad_1] Krystal Biotech’s Jeune reports promising phase 1 data on wrinkles drug [ad_2] Source: (*1*)
[ad_1] Invivyd down 18% despite Pemgarda COVID risk reduction data [ad_2] Source: Seekingalpha
[ad_1] matejmo/E+ by way of Getty Images Patients handled with Invivyd’s (NASDAQ:IVVD) Pemgarda (pemivibart) confirmed an 84% relative risk reduction in symptomatic COVID-19 in comparison with…